Literature DB >> 19009210

Idiopathic pulmonary fibrosis and emphysema in smokers.

Denise Rossato Silva1, Marcelo Basso Gazzana, Sérgio Saldanha Menna Barreto, Marli Maria Knorst.   

Abstract

OBJECTIVE: To describe the clinical and functional findings recently reported in the medical literature for patients diagnosed with emphysema involving the upper lobes and idiopathic pulmonary fibrosis (IPF) involving the lower lobes.
METHODS: Eleven patients with emphysema and IPF were identified retrospectively. All of the patients underwent high-resolution computed tomography of the lung and pulmonary function tests.
RESULTS: Of the 11 patients, 8 were male and 3 were female. The mean age was 70.7 +/- 7.2 years (range, 61-86 years). All of the patients were smokers (mean smoking history, 61.5 +/- 43.5 pack-years). The mean values of forced vital capacity (FVC), forced expiratory volume in one second (FEV1) and FEV1/FVC were 72.1% +/- 12.7%, 68.2% +/- 11.9% and 74.4 +/- 10.8, respectively. Lung volumes were normal in 7 patients. A restrictive pattern was observed in 3 patients, and hyperinflation was present in one. The diffusing capacity was moderately-to-severely reduced in all of the patients (mean, 27.7% +/- 12.9% of predicted). Ten of the 11 patients performed the six-minute walk test. The mean distance covered was 358.4 +/- 143.1 m, and 9 of the 10 patients presented desaturation >or= 4%. Echocardiographic findings suggestive of pulmonary hypertension were present in 4 patients (mean systolic pulmonary artery pressure, 61.8 mmHg; range, 36-84 mmHg).
CONCLUSIONS: The concomitant presence of emphysema and IPF causes characteristic changes on pulmonary function tests. The most significant finding is a discrepancy between diffusing capacity and spirometry results.

Entities:  

Mesh:

Year:  2008        PMID: 19009210     DOI: 10.1590/s1806-37132008001000005

Source DB:  PubMed          Journal:  J Bras Pneumol        ISSN: 1806-3713            Impact factor:   2.624


  8 in total

1.  Effects of cigarette smoke extract on A549 cells and human lung fibroblasts treated with transforming growth factor-beta1 in a coculture system.

Authors:  Yin Liu; Wei Gao; Deping Zhang
Journal:  Clin Exp Med       Date:  2009-11-19       Impact factor: 3.984

2.  Cigarette smoke extract induces the epithelial-to-mesenchymal transition via the PLTP/TGF-β1/Smad2 pathway in RLE-6TN cells.

Authors:  Hong Chen; Feng-Ping Wu; Yong-Zhen Yang; Xiu-Ying Yu; Lu Zhang; Hui Zhang; Ya-Juan Chen
Journal:  Toxicol Res (Camb)       Date:  2016-12-23       Impact factor: 3.524

Review 3.  Combined pulmonary fibrosis and emphysema syndrome: a review.

Authors:  Matthew D Jankowich; Sharon I S Rounds
Journal:  Chest       Date:  2012-01       Impact factor: 9.410

4.  Post-tuberculosis lung disease: a comparison of Brazilian, Italian, and Mexican cohorts.

Authors:  Denise Rossato Silva; Alana Ambos Freitas; Amanda Reis Guimarães; Lia D'Ambrosio; Rosella Centis; Marcela Muñoz-Torrico; Dina Visca; Giovanni Battista Migliori
Journal:  J Bras Pneumol       Date:  2022-05-13       Impact factor: 2.800

5.  Combined Pulmonary Fibrosis and Emphysema Syndrome: A New Phenotype within the Spectrum of Smoking-Related Interstitial Lung Disease.

Authors:  Karina Portillo; Josep Morera
Journal:  Pulm Med       Date:  2012-02-09

Review 6.  Combined pulmonary fibrosis and emphysema: an increasingly recognized condition.

Authors:  Olívia Meira Dias; Bruno Guedes Baldi; André Nathan Costa; Carlos Roberto Ribeiro Carvalho
Journal:  J Bras Pneumol       Date:  2014 May-Jun       Impact factor: 2.624

7.  HRCT diagnosis of combined pulmonary fibrosis and emphysema in a patient of chronic obstructive pulmonary disease with pulmonary hypertension and clinical or radiograph suspicion of pulmonary fibrosis.

Authors:  Kataveeranahally Shekar Manjunath; Hirennappa Udnur
Journal:  BJR Case Rep       Date:  2016-11-02

Review 8.  Comorbidities and Complications in Idiopathic Pulmonary Fibrosis.

Authors:  Esteban Cano-Jiménez; Fernanda Hernández González; Guadalupe Bermudo Peloche
Journal:  Med Sci (Basel)       Date:  2018-08-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.